52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Regeneron Says FDA Has Accepted For Priority Review Dupixent® (Dupilumab) For Children Aged 6 To 11 Years With Moderate-To-Severe Atopic Dermatitis
Regeneron Pharmaceuticals- Preliminary U.S. Net Product Sales Of Eylea Injection Of About $4.64 Bln For 2019
Regeneron Announces Encouraging Garetosmab Phase 2 Results In Patients With Ultra-Rare Debilitating Bone Disease
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
777 Old Saw Mill River Rd
P. Roy Vagelos
Chairman of the Board, Director
Leonard S. Schleifer
President, Chief Executive Officer, Director
Robert E. Landry
Chief Financial Officer, Executive Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Food & Drug Administration (FDA) regulatory body has accepted for priority review the use of Sanofi and Regeneron's Dupixent product for children aged 6-11 with moderate-to-severe eczema, the companies said.
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic bone disorder showed a nearly 90% reduction in new lesions compared to placebo, in a mid-stage study.
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic disorder proved more effective than placebo in reducing bone lesions.
(This November 8 story corrects spelling of analytics firm ESGauge, paragraph 10)
* S&P 500 directors' average compensation above $300,000 in 2018
Drugmaker Regeneron Pharmaceuticals Inc <REGN.O> beat analysts' estimates for third-quarter profit on Tuesday, boosted by higher demand for its blockbuster eye drug, Eylea, and eczema therapy Dupixent.
Nov 5 - Regeneron Pharmaceuticals Inc reported a 12.6% rise in third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent.
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.
Regeneron Pharmaceuticals Inc said on Monday its experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death, in a trial evaluating four treatments for infections caused by the deadly virus.
Regeneron Pharmaceuticals Inc <REGN.O> beat analysts' estimates for second-quarter profit and revenue on Tuesday, boosted by double-digit sales growth of its blockbuster treatment Eylea in the United States.
Regeneron Pharmaceuticals Inc reported better-than-expected quarterly revenue on Tuesday, boosted by demand for its blockbuster eye drug, Eylea.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.
The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.
The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent, as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.
Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.
The U.S. Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged between 12 and 17, a boost for both the companies in the world's largest market for drugs.
The U.S. Food & Drug Administration on Monday approved use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.